Home › Funds › MPM BioImpact LLC › TVTX

MPM BioImpact LLC position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

MPM BioImpact LLC reported holding 1,122,731 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$63.8M, representing 3.89% of its reported portfolio and ranking #7 among its reported holdings. MPM BioImpact LLC has disclosed TVTX holdings in 3 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.12M sh
Reported value held$63.78M
Portfolio Weight3.89%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How MPM BioImpact LLC's TVTX position evolved

MPM BioImpact LLC first disclosed a stake in TVTX in Q3 2023 at 552,846 shares (US$4.9M). The position peaked in Q2 2026 at 1,122,731 shares, worth US$63.8M. Across 3 filings, MPM BioImpact LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,122,731 shares valued at US$63.8M — a reduction of -10,634 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 552.85K $4.94M New
Q1 2026 1.13M $33.67M New
Q2 2026 1.12M $63.78M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has MPM BioImpact LLC held TVTX?

MPM BioImpact LLC has disclosed TVTX holdings in 3 of the last 12 reported quarters, going back to Q3 2023.

What is MPM BioImpact LLC's current position in TVTX?

As of Q2 2026, MPM BioImpact LLC holds 1.12M shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $63.78M, representing 3.89% of its reported portfolio and ranking #7.

Has MPM BioImpact LLC been buying or selling TVTX?

In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in TVTX. The position peaked in Q2 2026 at 1.12M shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.